The Second Clinical School, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, South China University of Technology, Guangzhou, 510080, Guangdong, China.
Travel Med Infect Dis. 2020 May-Jun;35:101647. doi: 10.1016/j.tmaid.2020.101647. Epub 2020 Apr 2.
The novel coronavirus infection that initially found at the end of 2019 has attracted great attention. So far, the number of infectious cases has increased globally to more than 100 thousand and the outbreak has been defined as a pandemic situation, but there are still no "specific drug" available. Relevant reports have pointed out the novel coronavirus has 80% homology with SARS. In the difficulty where new synthesized drug cannot be applied immediately to patients, "conventional drug in new use" becomes a feasible solution. The first medication experience of the recovered patients in the US has led remdesivir to be the "specific drug". China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19). We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus. Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19.
新型冠状病毒感染于 2019 年末首次发现，引起了极大关注。截至目前，全球感染病例已超过 10 万例，疫情已被定义为大流行，但仍没有“特效药”可用。相关报道指出，新型冠状病毒与 SARS 有 80%的同源性。在新合成药物不能立即应用于患者的困难情况下，“新药新用”成为一种可行的解决方案。美国康复患者的首次用药经验使瑞德西韦成为“特效药”。中国也立即采取行动，将瑞德西韦投入临床试验，旨在将其应用于 COVID-19 的临床治疗。我们从新型冠状病毒感染的结构、免疫原性和发病机制入手，进一步分析了瑞德西韦的药理作用和以往的试验，以确定对 COVID-19 进行实验的可行性。
